A skin and skin structure infection is a bacterial infection of skin and skin related tissues such as Epidermis tissue. Acute bacterial skin and skin structure infections is a cluster of common types of infection including abscesses, cellulitis, and wound infections, which requires an immediate effective antibacterial treatment, as part of a timely and cautious management.
A skin and skin structure infection may be complicated skin and skin structure infection or uncomplicated skin and skin structure infection. The uncomplicated group includes simple abscesses, impetiginous lesions, furuncles, and cellulitis mainly caused by Staphylococcus aureus and Streptococcus pyogenes. The complicated group includes infections either involving deeper soft tissue or requiring significant surgical intervention such as infected ulcers, burns, and major abscesses or a significant underlying disease.
Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market - Impact of the Coronavirus (COVID-19) Pandemic
The COVID-19 pandemic is expected to hamper growth of the global acute bacterial skin and skin structure infections market, owing to restriction in the supply chain of drugs during the COVID-19 pandemic. For instance, according to data reported by United Nations Office on Drugs and Crime in July 2020, the effective measures taken to control the spread of COVID-19 pandemic has at the end badly affected to drug supply chain. Many countries across the world have reported an overall shortage of many types of drugs at the retail level. Supply chain affected the transport and production of all kind of drugs, which is expected to hamper the market of acute bacterial skin and skin structure infections.
Break in medical treatment for many patients suffering from skin disease, during COVID-19 pandemic is expected to hamper growth of the global acute bacterial skin and skin structure infections market. For instance, according to data published in December, 2020, by National Institute of Health, U.S., due to lockdown imposed in many countries, as a measure to control COVID-19 disease affected health care industries and patients. The lockdown resulted in the pause of medical treatment of existing skin diseases for many patients. This is expected to hinder growth of the global acute bacterial skin and skin structure infections market.
The global acute bacterial skin and skin structure infections market is estimated to be valued at US$ 3,466.6 Mn in 2022 and is expected to exhibit a CAGR of 6.0% over the forecast period (2022-2030)
Figure 1: Global Acute Bacterial Skin and Skin Structure Infections Market Share, (%), Analysis, By Drug Type, 2022
Market players are launching new products, in order to expand their product portfolio. This is expected to drive growth of the global acute bacterial skin and skin structure infections market over the forecast period.
Market players are involved in launching new drugs and this is expected to drive growth of the global acute bacterial skin and skin structure infections market over the forecast period. For instance, on July 7, 2021, Melinta Therapeutics, a pharmaceutical company, launched its product KIMYRSA. KIMYRSA is a lipoglycopeptide antibiotic that provide a complete course of treatment for acute bacterial skin and skin structure infections. KIMYRSA is effective in a single dose of 1200mg injection.
Key players are engaged in receiving approvals for product used to treat acute bacterial skin and skin structure infections from regulatory authorities and this is expected to drive growth of the global acute bacterial skin and skin structure infections market over the forecast period.
Product approvals by regulatory authorities is expected to drive growth of the global acute bacterial skin and skin structure infections market over the forecast period. For instance, on June 19, 2017, Melinta Therapeutics, a pharmaceutical company, announced that its product Baxdela (delafloxacin), received approval from the U.S. Food and Drug Administrator (U.S. FDA), which is utilized in the treatment of acute bacterial skin and skin structure infections caused by vulnerable bacteria. Baxdela is a fluoroquinolone that shows activity against both gram-positive and gram-negative bacteria, as well as against methicillin-resistant Staphylococcus aureus.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2021 | Market Size in 2022: | US$ 3,466.6 Mn |
| Historical Data for: | 2017 to 2020 | Forecast Period: | 2022 to 2030 |
| Forecast Period 2022 to 2030 CAGR: | 6.0% | 2030 Value Projection: | US$ 5,512.1 Mn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
Fresenius SE & Co. KGaA, Pfizer, Inc., Amneal Pharmaceuticals LLC, Intas Pharmaceuticals Ltd., Cadila Healthcare Ltd., Glenmark Pharmaceuticals Ltd, GlaxoSmithKline plc., Sun Pharmaceutical Industries Ltd., Sandoz Inc., Aurobindo Pharma Ltd., AbbVie, Inc., Melinta Therapeutics, Inc., Accord Healthcare Ltd., Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., and Paratek Pharmaceuticals, Inc., |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Global Acute Bacterial Skin and Skin Structure Infections Market – Restraints
The increasing side effects associated with the available drugs such as Tigecycline for the treatment of acute bacterial skin and skin structure infections is expected to hamper growth of the global acute bacterial skin and skin structure infections market, over the forecast period. For instance, according to the National Institute of Health, U.S., Tigecycline injection have many side effects such as dizziness, vomiting, diarrhea, nausea, headache, pain, itching of the vagina etc. These side effects may turn into severe symptoms such as heart attack or some forms of cancer. Tigecycline injection are used for the treatment of acute bacterial skin and skin structure infections. Thus, side effects of these drugs will hamper growth of the global acute bacterial skin and skin structure infections market.
Global Acute Bacterial Skin and Skin Structure Infections Market – Regional Analysis
On the basis of region, the global acute bacterial skin and skin structure infections market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa
Among regions, North America acute bacterial skin and skin structure infections market is expected to hold a dominant position during the forecast period, owing to increasing product approvals by regulatory authorities. For instance, in October, 2018, Mylan Laboratories Limited, a U.S.-based pharmaceuticals company, announced that the U.S. Food and Drug Administration approved vancomycin hydrochloride injection. Vancomycin hydrochloride injection is a prescription medicine used to treat the symptoms of infection caused by MRSA (methicillin-resistant Staphylococcus aureus) skin and skin suture infections, lower respiratory tract infections, etc.
Furthermore, Europe is also estimated to witness significant growth in the global acute bacterial skin and skin structure infections market, owing to increasing research and development activities by key players for development of novel acute bacterial skin and skin structure infections. For instance, in October 2019, GlaxoSmithKline plc, a United Kingdom based pharmaceutical and biotechnology company, announced that it has begun a phase III clinical trial for examining gepotidacin, which is the first new chemical class of antibiotics called triazaacenaphthylene bacterial topoisomerase inhibitors. The phase III trials are carried out in patients with uncomplicated urinary tract infection, urogenital gonorrhea, and acute bacterial skin and skin structure infections.
Figure 2: Global Acute Bacterial Skin and Skin Structure Infections Market (US$ Mn), by Region, 2022
Global Acute Bacterial Skin and Skin Structure Infections Market – Competitive Landscape
Major players operating in the global acute bacterial skin and skin structure infections market include Fresenius SE & Co. KGaA, Pfizer, Inc., Amneal Pharmaceuticals LLC, Intas Pharmaceuticals Ltd., Cadila Healthcare Ltd., Glenmark Pharmaceuticals Ltd, GlaxoSmithKline plc., Sun Pharmaceutical Industries Ltd., Sandoz Inc., Aurobindo Pharma Ltd., AbbVie, Inc., Melinta Therapeutics, Inc., Accord Healthcare Ltd., Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., and Paratek Pharmaceuticals, Inc.,
Acute bacterial skin and skin structure infections is a collection of common types of infection including abscesses, cellulitis, and wound infections, which requires an immediate effective antibacterial treatment as part of a timely and careful management.
Drug-resistant bacteria such as methicillin-resistant Staphylococcus aureus causing acute bacterial skin and skin structure infections are more challenging to treat due to lack of availability of effective antibiotics. Acute bacterial skin and skin structure infections may be acquired through hospitals, as well as community. Methicillin-resistant Staphylococcus aureus may appear in a community among younger people who had not been previously exposed to hospitals or healthcare institutions, who may instead have been colonized through sporting activities, crowding, and intravenous drug abuse.
Market Dynamics
Market players are acquiring drug distribution rights in a country, which is expected to drive the global acute bacterial skin and skin structure infections market, over the forecast period. For instance, in March 2020, Sandoz, a pharmaceutical company acquired distribution rights of daptomycin 500mg injection and fosaprepitant 150mg for injection in the U.S. from BE Pharmaceuticals, a pharmaceutical company. This step was taken to strengthen the company's plan to grow its injectable portfolio and contributions in the hospital. Daptomycin is a naturally occurring lipopeptide antibiotic used in the treatment of acute bacterial skin and skin structure infections.
Increasing research and development by the key players for the development of new drugs to treat global acute bacterial skin and skin structure infections is expected to propel growth of the global acute bacterial skin and skin structure infections market. For instance, on September 28, 2020, TenNor Therapeutics Limited, a global clinical-stage company completed Phase II study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of TNP-2092 to treat acute bacterial skin and skin structure infection in adults. TNP-2092 was compared to vancomycin in a double-blind randomized, phase-II clinical trial for the treatment of confirmed or suspected Gram-positive ABSSSI. The study has been completed, and results are awaited.
Key features of the study:
Detailed Segmentation:
“*” marked represents similar segmentation in other categories in the respective section.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients